Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was slightly extended in our own case — was refreshing and invigorating, because that oh-so-familiar routine of deadlines, calls, meetings, and the like has, of course, returned. The world, after all, keeps spinning now matter how hard you might push back. So time to fire up the coffee kettle and get cracking. As always, here are some tidbits to get you started. Hope you conquer the world today and please do keep in touch if you hear something juicy or just plain curious. …

Once again, Roche’s (RHHBY) $4.3 billion takeover of Spark Therapeutics (ONCE) has been delayed, possibly beyond the first half of the year, as regulators continue to scrutinize the deal for its effect on competition, Reuters writes. Both companies received a request for more information from the Federal Trade Commission in connection with its review. And the U.K. Competition and Markets Authority has opened an investigation. Roche wants to buy Spark for an experimental gene therapy for hemophilia A and a platform to develop other treatments for genetic diseases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy